Earnings
GlaxoSmithKline exceeded expectations for its first-quarter sales and earnings forecasts. This was largely driven by its sales of Xevudy, an antibody treatment against COVID-19 it developed with Vir Biotechnology, and its Shingrix vaccine against shingles.
Swiss pharma giant Roche predicts a revenue slowdown related to its COVID-19 products and the increasing challenge of biosimilar drugs.
Although treating patients is the top priority of the biopharma industry, there’s no doubt that money is the driver. This is a broad look at the current state of biopharma bucks.
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
Coeptis Therapeutics is merging with special purpose acquisition company Bull Horn Holdings in a definitive deal worth around $175 million.
Halozyme Therapeutics announced that it is acquiring Antares Pharma for $960 million in cash. The news caused Antares stock to rocket 47% in premarket trading.
The funding will be used to push forward Aurion’s cell therapy program for corneal edema secondary to endothelial dysfunction.
The week began with new partnerships formed in the life sciences industry as several firms entered into licensing deals and collaboration commitments. Here’s a look at the latest.
GENFIT delivered on its promise to improve its financial situation in the year to December 31, 2021, posting an income of $40.8 million USD from a loss of $20.3 million in the year prior.
Proceeds from the Series A will be used to further advance the company’s Kinetic Ensemble platform and accelerate its R&D pipeline.
PRESS RELEASES